Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Teva call volume above normal and directionally bullish
Bullish option flow detected in Teva (TEVA) with 17,095 calls trading, 1.7x expected, and implied vol increasing over 1 point to 42.32%. 3/14 ...
Senior Housing News2d
Trustwell Living Doubles Down on Data in Search of New Competitive Advantage
This article is part of your SHN+ subscription In 2025, the baby boomer generation is standing at the industry’s doorstep.
BioXcel Therapeutics strengthens cash position to advance SERENITY trial
BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...
JD Supra4d
Health Care Week in Review | Senate Holds Hearings for NIH and FDA Nominees; CMS, HRSA, and SAMHSA Advise Against Forms of Gender-Affirming Care
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...
manilatimes5d
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
and accepted a supplemental new drug application (sNDA) seeking the approval of sac-TMT monotherapy for patients with EGFR-mutant NSCLC who have failed after EGFR-TKI therapy. Currently, sac-TMT is ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
Heron Therapeutics: Four Horse Race Of Approved Therapies
Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last Hold rating in November 2024.
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data ...